Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Asset Writedowns and Impairment (2023 - 2025)

Spero Therapeutics (SPRO) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $600000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $600000.0, compared with a TTM value of $600000.0 through Sep 2025, down 88.69%, and an annual FY2023 reading of $5.3 million, up 735.59% over the prior year.
  • Asset Writedowns and Impairment was $600000.0 for Q3 2025 at Spero Therapeutics, down from $5.3 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $5.3 million in Q3 2023 and bottomed at $600000.0 in Q3 2025.